Nnennaya Duke, DO
Family Medicine · Waterbury, CTNPI 1992144190
Payments from drug & device makers
Across 42 payments — averaging $27.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$202
- Gilead$156
- AbbVie$124
- Corcept Therapeutics$112
- Pfizer$102
- GSK$69
- plus $401 from 13 others
What the payments were for
- Food & beverage$1,165100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $202 |
| Gilead | 5 | $156 |
| AbbVie | 5 | $124 |
| Corcept Therapeutics | 4 | $112 |
| Pfizer | 5 | $102 |
| GSK | 3 | $69 |
| AstraZeneca | 2 | $57 |
| Exact Sciences | 2 | $44 |
| Boehringer Ingelheim | 2 | $42 |
| Bayer | 2 | $41 |
| Lilly USA, LLC | 2 | $39 |
| Indivior Inc. | 1 | $38 |
| Braeburn Inc. | 1 | $25 |
| Viiv Healthcare Company | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Merck | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$119
How this compares
$1,165 in reported general payments places this provider in the 70th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $45,258 |
| JardianceEmpagliflozin | 22 | $26,061 |
| JanuviaSitagliptin Phosphate | 20 | $14,055 |
| TrulicityDulaglutide | 14 | $13,953 |
| FarxigaDapagliflozin Propanediol | 13 | $8,665 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,640 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $8,252 |
| Diclofenac Sodium | 68 | $1,758 |
| Ondansetron OdtOndansetron | 12 | $1,434 |
| Rosuvastatin Calcium | 89 | $1,406 |
| FenofibrateFenofibrate Nanocrystallized | 37 | $1,320 |
| Ventolin HfaAlbuterol Sulfate | 23 | $1,314 |
| Mometasone Furoate | 13 | $1,299 |
| Celecoxib | 43 | $1,099 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $202 | $45,25834 claims |
| Boehringer IngelheimJardiance | $42 | $26,06122 claims |
| MerckJanuvia, Janumet | $17 | $22,30732 claims |
| Lilly USA, LLCTrulicity | $39 | $13,95314 claims |
| AstraZenecaFarxiga | $57 | $8,66513 claims |
| GSKTrelegy Ellipta | $69 | $8,64011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Waterbury
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Andrew SelingerBristol$31K
- Helar CamposNew London$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.